Table 2.

Racial and ethnic differences in treatment-related outcomes and survival

Outcomes	No.	%	NH White (N = 497)		NH Black (N = 126)		Hispanic (N = 117)		Other (N = 82)		P
			No.	%	No.	%	No.	%	No.	%
Weeks at risk (follow-up)
Mean no. of weeks	96		103		73		104		78
Median no. of weeks	68		74		52		71		58
Treatment (N = 822)
Induction	572	70	336	68	86	68	94	80	56	68
Nonintensive	192	23	130	26	28	22	18	15	16	20
Supportive care	58	7	31	6	12	10	5	4	10	12
For patients receiving induction therapy (N = 572)
Treatment response after  induction											.01
Complete response	395	69	226	67	58	67	70	74	41	73
Cri	49	9	33	10	8	9	6	6	2	4
MLFS	7	1	2	1	0	0	5	5	0	0
PR	32	6	22	7	3	3	2	2	5	9
Treatment failure	89	16	53	16	17	20	11	12	8	14
Relapse (among the 483 responders)
No	266	55	157	55	34	49	45	54	30	63
Yes	184	38	115	41	26	38	29	35	14	29
Missing	33	7	11	4	9	13	9	11	4	8
For patients receiving nonintensive therapy (N = 192)
Relapse (among 72  responders)											.13
No	22	31	20	38	1	11	1	17	0	0
Yes	42	58	27	51	6	67	5	83	4	100
Missing	8	11	6	11	2	22	0	0	0	0
All AML regardless of treatment (N = 822)
Death within 90 days
No/missing	735	89	442	89	110	87	110	94	73	89
Yes	87	11	55	11	16	13	7	6	9	11
One-year relapse-free survival											.17
No/missing	412	50	240	48	72	57	54	46	46	56
Yes	410	50	257	52	54	43	63	54	36	44
Two-year relapse-free survival											.17
No/missing	589	72	352	71	96	76	77	66	64	78
Yes	233	28	145	29	30	24	40	34	18	22
One-year overall survival											.13
No/missing	228	28	138	28	43	34	24	21	23	28
Yes	594	72	359	72	83	66	93	79	59	72
Two-year overall survival											.17
No/missing	341	41	212	43	59	47	42	36	28	34
Yes	481	59	285	57	67	53	75	64	54	66

P < .20 is suppressed.